Javascript must be enabled to continue!
Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
View through CrossRef
<b>Introduction</b>: Slow coronary flow (SCF) is an angiographic phenomenon characterized by delayed opacification of epicardial coronary arteries without an obstructive coronary disease. Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels seem closely related to atherosclerosis due to increased inflammation and prothrombotic state. We studied whether circulating suPAR is related to SCF.<br />
<b>Material and methods</b>: The present study was cross-sectional and observational. It included 75 individuals who underwent coronary angiography with suspected CAD and had angiographically normal coronary arteries of varying coronary flow rates. The relationship between suPAR, C-reactive protein (CRP) and SCF was investigated. Forty patients with isolated SCF (mean age: 46.0 ±4.14 years) and 35 age- and gender-matched control participants with normal coronary flow (NCF) and normal coronary arteries (NCA) (mean age: 46.0 ±5.7 years) were included in the study. We used logistic regression analysis to determine the predictors of SCF.<br />
<b>Results</b>: The clinical characteristics were not statistically significantly different between SCF and NCA groups. Serum suPAR level was significantly higher in the SCF group than the control group (2.5–5.4 ng/ml vs. 0.1–1.4 ng/ml; p < 0.001). Also the serum CRP level was higher in the CSF group than the control group (1.57 ±0.43 mg/l vs. 0.53 ±0.23 mg/l; p < 0.001).<br />
<b>Conclusions</b>: This study revealed significantly increased serum suPAR levels in patients with SCF. Although we cannot draw conclusions on the underlying pathological process of SCF, we believe that these findings may be pioneering for further studies investigating the specific roles of circulating suPAR in the SCF phenomenon in the coronary vasculature.
Title: Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
Description:
<b>Introduction</b>: Slow coronary flow (SCF) is an angiographic phenomenon characterized by delayed opacification of epicardial coronary arteries without an obstructive coronary disease.
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels seem closely related to atherosclerosis due to increased inflammation and prothrombotic state.
We studied whether circulating suPAR is related to SCF.
<br />
<b>Material and methods</b>: The present study was cross-sectional and observational.
It included 75 individuals who underwent coronary angiography with suspected CAD and had angiographically normal coronary arteries of varying coronary flow rates.
The relationship between suPAR, C-reactive protein (CRP) and SCF was investigated.
Forty patients with isolated SCF (mean age: 46.
0 ±4.
14 years) and 35 age- and gender-matched control participants with normal coronary flow (NCF) and normal coronary arteries (NCA) (mean age: 46.
0 ±5.
7 years) were included in the study.
We used logistic regression analysis to determine the predictors of SCF.
<br />
<b>Results</b>: The clinical characteristics were not statistically significantly different between SCF and NCA groups.
Serum suPAR level was significantly higher in the SCF group than the control group (2.
5–5.
4 ng/ml vs.
0.
1–1.
4 ng/ml; p < 0.
001).
Also the serum CRP level was higher in the CSF group than the control group (1.
57 ±0.
43 mg/l vs.
0.
53 ±0.
23 mg/l; p < 0.
001).
<br />
<b>Conclusions</b>: This study revealed significantly increased serum suPAR levels in patients with SCF.
Although we cannot draw conclusions on the underlying pathological process of SCF, we believe that these findings may be pioneering for further studies investigating the specific roles of circulating suPAR in the SCF phenomenon in the coronary vasculature.
Related Results
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
Systemic chronic inflammation (SCI) is persistent, health-damaging, low-grade inflammation that plays a major role in immunosenescence and in development and progression of many di...
Thrombo-inflammatory biomarkers to predict sepsis outcome
Thrombo-inflammatory biomarkers to predict sepsis outcome
Background: Sepsis has been redefined recently as life-threatening organ dysfunction caused by dysregulated host responses to infection and septic shock. Soluble urokinase plasmino...
Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response
Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response
BACKGROUND:
Despite advances in lung cancer treatment, most lung cancers are diagnosed at an advanced stage. Expression of microRNA10b (miR-10b) and fibrinolyti...
SuPAR, an emerging biomarker in acute kidney injury in ICU patients
SuPAR, an emerging biomarker in acute kidney injury in ICU patients
Acute kidney injury (AKI) is a critical condition with delayed diagnosis when relying solely on plasma creatinine levels. This study investigates the role of soluble urokinase plas...
UNDERSTANDING THE RELATIONSHIP BETWEEN URINARY SUPAR AND TREATMENT RESPONSE IN PEDIATRIC NEPHROTIC SYNDROME
UNDERSTANDING THE RELATIONSHIP BETWEEN URINARY SUPAR AND TREATMENT RESPONSE IN PEDIATRIC NEPHROTIC SYNDROME
Objectives: To investigate the relationship between the concentration of urinary soluble urokinase plasminogen activator (suPAR) pretreatment with the treatment responsiveness in c...
Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument
Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument
Background:
Deregulation in the urokinase-type plasminogen activator receptor (uPA/uPAR) system is reported in many diseases where the immune system is activate...
Kinetics Of Plasminogen Activation By Tissue Plasminogen Activator. Role Of Fibrin
Kinetics Of Plasminogen Activation By Tissue Plasminogen Activator. Role Of Fibrin
The activation of human plasminogen (P) by two-chain tissue plasminogen activator (A) was studied in the presence of fibrin films (F) of increasing size and surface density. Initia...

